Introduction
The two steroid hormones, estrogen and progesterone, play vital roles in maintaining pregnancy and initiating labor (51) and more generally in myometrial physiology and contractility. Progesterone maintains uterine quiescence during pregnancy, while estrogen induces uterine contraction at labor (49) (50) (51) . These hormones fluctuate relative to each other throughout life from puberty, through the fertile years, to the post-fertile years and also within these life stages during specific physiological states such as estrous, pregnancy, labor and menopause. Furthermore, both hormones have profound effects on pathophysiological conditions such as leiomyoma, endometriosis and endometrial cancer.
In maternal physiology these hormones induce changes that prepare the mother for pregnancy and aid in conceptus development (11) . In most species, a sharp decline in circulating progesterone and an increase in estrogen are observed towards parturition (11, 38) . However, in humans, no marked difference in the levels of circulating progesterone or estrogen is noted before or at term (51) . Hence, in humans, withdrawal of progesterone and responsiveness of the myometrium to circulating estrogen during labor is believed to occur at a functional level, with changes in hormone receptors playing a more important role than the circulating levels of the hormone themselves (50) . Understanding the molecular mechanisms underlying the transition of the uterus from a relatively quiescent organ to an actively contracting organ is of utmost importance in predicting and treating disorders of pregnancy, including preterm labor.
Several functional genomics studies have been carried out across a range of species, including humans, in order to understand the molecular changes underlying the transition of the quiescent uterus to a rhythmic and actively contracting organ during parturition (1, 5, 8, 12, 13, 16, 17, 26, 31, 53, 56, 60) . In their analysis of all published microarray-based transcriptomic analyses of labouring and nonlaboring myometrium, Breuiller-Fouche and colleagues identified little overlap between results from different studies (10) . However, each study has identified key molecular regulators and pathways that have broadened our understanding of the complex mechanisms underlying myometrial quiescence and activation. Differences in the cascade of events that precede human labor, compared to well-studied animal models, makes extrapolation of conclusions from model organisms to humans difficult. The stringency in ethical regulations and difficulty in obtaining patient samples understandably makes human studies challenging. Therefore, developing a model cell culture system to study biological events associated with progesterone and estrogen is both relevant and important.
The human myometrium is composed of two distinct smooth muscle layers with a surface epithelium and a supporting capillary network and stromal cells. Clearly a smooth muscle cell culture system cannot model all the intricate interactions within the native myometrium in vivo, nor can it replicate the complex cell signalling and hormonal interactions, as well as other physiological and pharmacological changes that occur in the human myometrium in pregnancy and at the onset of labor.
Isolated in vitro cell culture systems, while not mimicking the pregnant laboring human myometrium, can, however yield important clues as to the roles played by the smooth muscle cells -roles that can be obscured in whole tissue studies. As a result, studies of this nature can also provide important clues as to the overall myometrial system, which can inform the complex physiological events occurring in vivo in pregnant myometrium at the onset of labor.
No transcriptomic study has yet been carried out to investigate the combined effects of 17β-estradiol (E2) and progesterone (P4), and the impact of the progesterone inhibitor (RU486) on cultured uterine smooth muscle cells in relation to myometrial contractility, though an in vitro study has recently been published on the gene expression profile of immortalised human myometrial cells primarily in response to progesterone (69) . Global transcriptomic profiling of cultured human uterine smooth muscle cells (hUtSMCs) following combined P4 and E2 steroid hormone treatments, including combined hormone treatment in the presence of the progesterone antagonist RU486 to functionally withdraw progesterone as occurs at human labor, is presented here.
Materials and methods

Cell culture and treatment:
The primary human uterine smooth muscle cells (hUtSMCs) used were obtained from Lonza (CLONETICS™ Uterine Smooth Muscle Cell Systems, CC-2562) and are identical to the Cambrex product described in other published studies (20, 70) . It has previously been shown that E2 treatment of these hUtSMC cells produces effects expected of steroid hormones on myometrial cells, for example, both mRNA and protein expression of previously reported E2-responsive genes, CD38 (23) and GJA1 (also known as connexin CX43) (22) responded as expected to E2 treatment (14) . As a control for the Lonza CLONETICS™ cells, normal primary smooth muscle myometrial cells were isolated from a pregnant non-labouring patient, with ethical approval having been obtained through In brief, at 100 % confluence the following additions were made to flasks 1-6: (1) no addition, (2) 10 nM 17-estradiol (E2) (Sigma Aldrich), (3) & (6) 100 nM progesterone (P4) (Sigma Aldrich), and (4) & (5) P4 + E2 (P4/E2 samples). 48 h after these additions, flasks (5) and (6) were supplemented with 1 μM RU486 (Sigma Aldrich). Flasks (4) and (5) had been primed at 80 % confluence by supplementation with 100 nM progesterone (P4). All samples were harvested 72 h after hormonal treatments at 100% confluence. Each single experiment consisted of all six treatments and each experiment was repeated three times on different occasions (18 samples).
Final concentrations of E2 (14) , P4 and RU486 were determined empirically. For this study, the optimal level of P4 addition was determined by real time RT-PCR quantification of the BCL2 gene, a known P4-responsive gene (48, 72) , over the range 10-500 nM P4 (data not shown). Induced expression did not increase substantially above 100 nM P4. Again following the gene expression level of BCL2, it was shown that 1μM RU486 significantly inhibited the effects of 100 nM P4. These concentrations are in line with similar studies (41, 47, 72) .
RNA isolation and quantitative RT-PCR:
RNA was isolated using the RNeasy Mini Kit following the manufacturer's protocol (Qiagen). RNA was quantified using the NanoDrop 1000 (Thermo Scientific) and the quality checked using a Bioanalyzer 2100 (Agilent Technologies). Polymerase chain reaction (PCR) was performed using the GoTaq® DNA Polymerase Kit (Promega) according to manufacturer's protocol. The list of genes and corresponding primers sequences obtained from PrimerDepot (19) (http://primerdepot.nci.nih.gov/) are provided in Table 1 . Reverse transcription (RT) was carried out using 20 U Superscript II Reverse Transcriptase (Invitrogen) with 2 μg RNA and 50 pmol Oligo dT. Real-time RT-PCR was carried out using the QuantiTect SYBR Green PCR Kit (Qiagen) and QuantiTect primers for BCL2 (QT00025011), TTPA (QT00012040) and EMILIN2 (QT00092246) and subjected to 40 cycles of amplification in an ABI StepOnePlus™ Real-Time PCR System (Applied Biosystems). All gene quantities were normalised to the housekeeping gene (GAPDH). Relative expression was evaluated by the ΔΔCt method.
Microarray hybridization and data analysis:
Isolated RNA was amplified using the Amino Allyl MessageAmp II aRNA Amplification Kit oligonucleotide probes representing approximately 25,100 unique genes and 39,600 transcripts, excluding control oligos. All hybridizations were carried out using the OpArray (Operon) hybridization and wash solutions as recommended by the manufacturer. Slides were scanned at 543 nm (Cy3) with a ScanArray Express HT scanner (Perkin Elmer) and quantified using GenePix 6.0 software (Axon Instruments, Inc.). For this particular dataset all slides were scanned three times successively and the median raw values only were inputted into GeneSpring. All data normalization and analyses were carried out in GeneSpring GX12.0 (Agilent Technologies). Data was log transformed and normalized by the Percentile Shift Method using the 75th percentile. Subsequently all normalized data was baseline transformed to the median of all samples. Intensity values for all entities (35, 357) were initially filtered to exclude values which were less than 50 in at least 2 of 6 conditions (CON, E2, P4, P4/E2, P4/E2 + RU486 or P4 + RU486). Significantly differentially expressed genes were identified based on log values using a moderated t-test (68) , with a P-value cutoff of 0.05 and a fold change minimum of 1.5 fold. No multiple testing correction was applied. All data has been submitted to the Gene Expression Omnibus (GSE59231).
Gene ontology and transciptional analysis of genes:
A web-based system for the detection of over-represented conserved transcription factor binding sites, oPOSSUM, was used to analyse sequences of specific, apparent co-regulated, gene sets (33) . Initially the genes differentially expressed on addition of individual hormones, P4 or E2, were analysed.
Transcription factor binding sites were considered significant if either the Z-score was greater than 10 or the Fisher score was greater than 5. Gene ontology (GO) analysis was performed using DAVID (Database for Annotation, Visualization and Integrated Discovery, v6.7) (21). Some gene annotation was not recognized by DAVID and some genes had no GO annotation. Individual analyses were carried out on upregulated, downregulated and pooled regulated genes. The biological process GO category was given most weight though cell component and molecular function categories were noted where relevant, and other pathway and term analysis approaches using Panther, KEGG and PIR keywords (all within DAVID) were also included.
Statistical analysis:
All qPCR experiments were carried out in triplicate. Results are expressed as mean +/-standard deviation. P-values were used as a measure of the magnitude of the change and inter-subject variability among the treated and control samples. 
Results
Transcriptomic analysis of hUtSMCs after hormone treatment:
Cells were (1) untreated, or treated with (2) E2 alone, (3) P4 alone, (4) P4 and E2 in combination (P4/E2), (5) RU486 after P4/E2 incubation (P4/E2 + RU486) and (6) RU486 after P4 incubation (P4 + RU486). Cells in samples 4 & 5 were primed with P4 (see Figure 1 ). Unlike other model organisms (both primate and non-primate), the human myometrium is exposed to high concentrations of both estrogen and progesterone during pregnancy (3). To mimic this steroid hormone environment, cultured hUtSMCs were exposed to both 10 nM E2 and 100 nM P4 (concentrations correlating to circulating levels in mid to late pregnancy). P4 additions were made 24 h prior to E2 additions to mimic the earlier elevation of circulating P4 levels in pregnancy. A total of 18 slides were analysed representing all conditions (CON, E2, P4, P4/E2, P4/E2 + RU486 and P4 + RU486), with each condition analysed in three independent experiments.
A total of 796 genes (P<0.05, fold change>1.5-fold) showed significant differential expression following P4/E2 co-treatment of which 364 genes were up-regulated and 432 down-regulated (Supplemental data Table 1 ). Fifty three genes showed fold changes exceeding 5-fold following P4/E2 treatment, of which the top 20 are shown (Table 2 ). Although 796 genes were significantly modulated transcriptionally by the combination of P4/E2 only 28 and 23 of these genes also showed significantly altered transcriptional regulation by the individual hormones E2 and P4 respectively ( Figure 2 ). This suggests that the combined effect of the hormones was much greater than the sum of their individual effects. There were also genes whose expression suggested transcriptional modulation by the individual hormones (106 by P4, 110 by E2) and an absence of modulation by the combination of hormones ( Figure 2 ). This may indicate antagonistic effects of the individual hormones.
To identify genes that were differentially expressed in response to addition of the P4 antagonist RU486, the expression profile of cells co-treated with P4/E2 was compared to that of cells co-treated with P4/E2 to which RU486 was subsequently added (see Figure 1 ). The expression of 666 fully annotated genes (>1.5-fold) was altered in cultured hUtSMCs treated with P4/E2 + RU486 compared to cells treated with P4/E2. The expression of 304 genes was up-regulated and of 362 genes was down-regulated in this experimental group (Supplemental data Table 2 ). Seventy two genes showed fold changes exceeding 5-fold following P4/E2 + RU486 treatment, of which the top 20 are shown (Table 3 ).
The expression profiles of the significant P4/E2 differentially regulated genes (796 genes) showed modulated expression in some of the other conditions (E2, P4, P4 + RU486) but the vast majority showed reversal of transcriptional modulation in P4/E2 + RU486 conditions. Similarly the expression profiles of the significant P4/E2 ± RU486 differentially regulated genes (666 genes) showed modulated expression in some of the other conditions but the vast majority showed reversal of transcriptional modulation on addition of RU486. This suggested that virtually all P4/E2 regulated genes were also modulated by RU486 even though only approximately 25 % of genes were common to both sets. To show the similarity of the two sets all P4/E2 modulated genes and all P4/E2 ± RU486 modulated genes were separately clustered across all conditions investigated; both populations showed significant up-or down-regulation upon P4/E2 treatment and a return to near untreated levels following RU486 treatment. All regulated genes (here, for clarity, we only show the P4/E2 ± RU486 group, not the two groups) were clustered into five expression profile sets across all conditions ( Figure 3 ).
The genes of the major cluster (cluster 1) showed no altered transcriptional regulation by P4, but considerable up-regulation by the P4/E2 combination. RU486 restored expression levels to approximately those of the control. This cluster was mirrored by a second large cluster (cluster 2) that showed down-regulated transcription by the P4/E2 combination. RU486 again reversed P4/E2 effects.
A small cluster (cluster 3) was similar to cluster 2 but in addition these genes showed down-regulated transcription following RU486 treatment of P4 treated cells. Cluster 4 genes were down-regulated by E2 alone but up-regulated by the P4/E2 combination. Cluster 5 showed the strongest down-regulation of expression by the P4/E2 combination. Very few genes showed an expression profile different from the patterns shown in Figure 3 . Comparison of the expression profiles of P4/E2 + RU486 treated cells with cells treated with E2 alone, indicated that there were very few genes whose expression was differentially modulated between these two conditions, and insufficient to identify any novel GO term (data not shown). This and additional comparisons (e.g. CON vs P4+RU486 and CON vs P4/E2+RU486) generated gene lists for which GO analysis extracted very few terms of significance.
Therefore, there was no novel functional category outside that of its role as a progesterone antagonist that could be ascribed to the effect of RU486.
Since gene expression is a measure of the combined actions of different transcription factors, it was of interest to investigate how the genes of each of the five expression profile clusters differed in their transcription factor binding site makeup. Using the 796 genes differentially regulated by P4/E2 as representative of the five clusters, oPOSSUM, a web-based system for the detection of overrepresented conserved transcription factor binding sites, was used to analyse sequences of the gene set (33) . Initial interrogation of genes differentially expressed on addition of individual hormones, P4 or E2, identified a number of significant transcription factor binding sites. Two transcription factors from the hormone-nuclear receptor family (NR1H2::RXRA and NR3C1) were overrepresented on E2 treatment and four from the Rel family (NFATC2, NF-kappaB, RELA, NFKB1) of transcription factors were overrepresented on P4 treatment (Table 4) . Three of the five clusters of P4/E2 regulated genes (clusters 1, 2 and 3) showed significantly overrepresented binding sites for transcription factors.
Of note, the putative transcription factors associated with clusters 1 and 3 genes showed a high degree of overlap, including forkhead (FOX) factors, NKx factors, ARID3A, PDX1, HOXA5, SRY, and
PRRX2, yet the cluster 1 and cluster 3 gene expression profiles were almost opposites. Furthermore, forkhead factors, NKx factors and ARID3A were also significantly overrepresented in the E2 treated samples. 
Quantitative and semi-quantitative RT PCR:
Gene Ontology analysis of differentially expressed genes:
To understand the biological significance of the differentially expressed genes identified following addition of RU486 to P4/E2-treated hUtSMCs, gene ontology (GO) analysis was performed using DAVID (21) . Of the original significant 666 genes identified, GO analysis identified significant terms for 397 genes. The most enriched biological process cluster, which included mostly up-regulated genes, related to signal transduction ( Figure 5 ). In addition, using the other two GO categories (cell component and molecular function), it was clear that channel activity, transcription and translation were very significant but that most activity was associated with the plasma membrane of the cell.
Other gene ontology pathway and term analysis approaches using Panther, KEGG and PIR keywords (all within DAVID) reflected the initial GO analysis, though additional informative terms such as androgen and estrogen metabolism and cell surface receptor mediated signal transduction were also significant. The direction of regulation was clear for genes assigned to some GO terms: transcription, translation and metabolism terms included genes that were mainly down-regulated whereas cell were most notably overrepresented in the P4/E2 regulated genes (Table 4) suggesting that NFAT factors are important regulators of gene expression in these hormonal conditions (59). IL1RN was down-regulated 6.0-fold following addition of RU486, and since it antagonizes the pro-inflammatory interleukin 1, its down-regulation is essentially pro-inflammatory.
During the early stages of pregnancy, myometrial cells proliferate rapidly to accommodate the growing fetus (66) and reach a hypertrophic phase by mid-gestation (65) . Late pregnancy in the rat myometrium is marked by an increase in apoptosis. In our system with P4/E2 treatment there was a balance of up-and down-regulated apoptosis-related genes but on addition of RU486, pro-apoptotic genes were in general down-regulated. Elastin microfibril interface-located protein 2 (EMILIN2) expression was significantly down-regulated in P4/E2 + RU486-treated hUtSMCs compared to P4/E2-treated cells. EMILIN2 binds to TRAIL receptor DR4 to induce apoptosis (54) . The role of ribosomal proteins in regulating cell proliferation and as inducers of cell death is well studied. In the present study, ribosomal protein RPL23 was down-regulated (5.7-fold) in hUtSMCs treated with P4/E2+RU486. RPL23 blocks the interaction between tumor suppressor gene p53 and MDM2, activating p53 and thereby inhibiting cell proliferation (75) . These results correlate with those of a previous study in mouse myometrium, which also found that pro-apoptotic genes were down- shown by the failure of TTPA knockout mice to reach term after implantation due to severe defects in placental development, which can be rescued with α-tocopherol (vitamin E) supplementation (36) .
Gap junctions in myometrial strips can be protected from chemical damage by administration of α-
In oPOSSUM analysis (Table 4 ) of P4/E2 regulated genes one common motif is that for NFAT. It was also overrepresented in the E2-regulated genes but not evident in the P4-regulated genes. Five isoforms of NFAT are known; for four isoforms, signalling is mediated by the Ca 2+ /calmodulindependent phosphatase calcineurin and all are expressed in human myometrial cells (59). It has been shown that NFAT can respond to oxytocin pulses and regulate transcription by controlled translocation between the nucleus (on) and cytoplasm (off). NFAT could therefore be playing an important role in parturition by linking oxytocin and muscle contraction to NFAT transcriptional activation via Ca 2+ levels and calcineurin (59). There is also an overrepresentation of forkhead transcription factor-binding sites in genes regulated by the P4/E2 combination treatment. Forkhead transcription factors have been associated with TA-rich ESR1 sites as opposed to GC-rich ESR2 sites (44) . oPOSSUM analysis (Table 4 ) also identified genes regulated by the P4/E2 combination treatment with binding motifs for transcription factors NK-2/NK-3 (NKx2-5, NKx3-1 or NKx3-2), HOXA5 and ARID 3A. Nkx2-5 belongs to the NK-2 homeobox family and has been implicated in myocardial development, in both cardiomyocytes and smooth muscle (76) . In an in vitro model of smooth muscle differentiation, the promoter of the smooth muscle gamma isoactin gene has been shown to bind NK-2 and serum response factor (SRF) in intestinal smooth muscle cells (57). In uterine smooth muscle cells myocyte enhancer factor 2 (MEF2) is also bound in this complex (57).
Previous studies have also reported the up-regulation of several transcription factors associated with the transition from pregnant not-in-labor to laboring myometrium in rat, mouse and human (8, 16, 25, 28, 32, 53, 62, 69) .
Conclusions
In the past decade, several functional genomic studies have been conducted to decipher the complex molecular mechanisms involved in pregnancy and parturition across species. The key events that regulate pregnancy and parturition are diverse and often species-specific making extrapolation from model species to the human condition difficult. Understanding the underlying mechanisms in humans is of utmost importance for the diagnosis and treatment of preterm and post-term labor. Establishing an in vitro myometrial cell culture model system to study human pregnancy and labor, therefore, has many associated benefits. In this study we have modelled the effects of two major steroid hormones to identify differentially expressed genes associated with the physiology of pregnancy, labor, estrous and menopause, a model which also has possible implications for the pathophysiology of leiomyoma and endometrial cancer. Exposure of hUtSMCs to steroid hormonal conditions similar to those of the pregnant non-laboring myometrium (P4/E2 treatment) altered the expression of genes favouring muscle cell relaxation, increased cell proliferation and growth, and reduced immune and inflammatory responses. These findings were similar to previously published results on in vivo myometrial samples (32) . When progesterone was functionally withdrawn from the P4/E2 co-treated cell culture system, by using the progesterone antagonist RU486, the altered expression of genes 
